Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Trieb, K; Lechleitner, T; Lang, S; Windhager, R; Kotz, R; Dirnhofer, S.
Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Pathol Res Pract. 1998; 194(10):679-684
Doi: 10.1016/S0344-0338(98)80126-X
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Windhager Reinhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Although in recent years the outcome of patients with osteosarcoma has considerably been improved by combining neoadjuvant chemotherapy with radical surgery, there still remains the problem of nonresponse to chemotherapy. T-lymphocytes play a critical role in tumor immunology, and MHC molecules are of central importance in the regulation of the immune response. It is the aim of this study to investigate whether T-lymphocyte infiltration of osteosarcomas and HLA-DR expression on tumor cells and infiltrating immune cells are of predictive or diagnostic value. Expression of CD3, CD8 and HLA-II was evaluated immunohistochemically on paraffin-embedded sections of 35 patients with high-grade osteosarcoma at the time of biopsy before chemotherapy and correlated with histologic response to chemotherapy, tumor size, age, alkaline-phosphatase serum levels and duration of symptoms. Thirty-four patients with osteoblastoma (n = 7), osteoid osteoma (n = 7) or fibrous dysplasia (n = 20) served as controls. Osteosarcomas were infiltrated by CD3+ (33/35, 95%) and CD8+ T-lymphocytes (24/35, 68%), non malignant bone tumors by CD3+ in 91% (31/34) and CD8+ T-lymphocytes in 74% (25/34), respectively. T-lymphocytes were positive for HLA-DR expression in 29% (10/35) in osteosarcomas and in 11% (4/34) in non-malignant controls. Osteosarcoma cells were positive for HLA-DR in 11/35 (31%) and non-malignant tumor cells in only 9% (3/34). Therefore, HLA-DR is overexpressed in osteosarcoma (p < 0.05). HLA-DR expression on osteosarcoma cells showed a positive correlation with HLA-DR expression on lymphocytes (p < 0.001) as well as with duration of symptoms and age (p < 0.05). Response to preoperative chemotherapy, gender, tumor size and serum alkaline-phosphatase levels did not correlate with the expression of the molecules tested. Our results show that HLA-DR is overexpressed in osteosarcoma cells compared to non-malignant bone-tumors. This overexpression, however, fails to serve as a predictive marker for response to neoadjuvant chemotherapy. The same is also true for tumor-infiltrating lymphocytes expressing CD3, CD8 and HLA-DR. Increased HLA-DR expression in osteosarcoma is most likely due to the immune response against the tumor.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Alkaline Phosphatase - blood
- Antigens, CD3 - analysis
- Antigens, CD8 - analysis
- Bone Neoplasms - immunology
- Child - immunology
- Female - immunology
- Fibrous Dysplasia of Bone - immunology
- HLA-DR Antigens - immunology
- Humans - immunology
- Lymphocytes, Tumor-Infiltrating - immunology
- Male - immunology
- Middle Aged - immunology
- Neoadjuvant Therapy - immunology
- Osteoblastoma - immunology
- Osteoma, Osteoid - immunology
- Osteosarcoma - immunology
- Prognosis - immunology
- Survival Analysis - immunology
- T-Lymphocyte Subsets - immunology
- T-Lymphocytes - immunology
- Tumor Markers, Biological - immunology
- Find related publications in this database (Keywords)
- osteosarcoma
- HLA-DR
- T-lymphocyte
- chemotherapy
- predictive marker